
Manesh R Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3541258/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 883-891. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 Appropriateness Criteria for Cardiac Computed	13.9	8,006
2	Tomography and Cardiac Magnetic Resonance ImagingâŽâŽDeveloped in accordance with the principles and methodology outlined by ACCF: Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson ED, Wolk MJ, Allen JM, Raskin IE. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol 2005;46:1606–13 Journal of the American College of	1.2	1,326
3	Cardiology, 2006, 48, 1475-1497. Low Diagnostic Yield of Elective Coronary Angiography. New England Journal of Medicine, 2010, 362, 886-895.	13.9	1,326
4	Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. New England Journal of Medicine, 2015, 372, 1291-1300.	13.9	1,179
5	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2013, 309, 1268.	3.8	976
6	Global vascular guidelines on the management of chronic limb-threatening ischemia. Journal of Vascular Surgery, 2019, 69, 3S-125S.e40.	0.6	841
7	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. New England Journal of Medicine, 2017, 376, 1824-1834.	13.9	742
8	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. European Journal of Vascular and Endovascular Surgery, 2019, 58, S1-S109.e33.	0.8	741
9	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology, 2011, 58, e123-e210.	1.2	665
10	Detection of Myocardial Damage in Patients With Sarcoidosis. Circulation, 2009, 120, 1969-1977.	1.6	610
11	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	6.3	597
12	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, The, 2018, 391, 2346-2355.	6.3	597
13	ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2014, 63, 380-406.	1.2	580
14	Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine, 2020, 382, 1994-2004.	13.9	566
15	ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2010, 55, 2614-2662.	1.2	559
16	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal, 2011, 32, 2387-2394.	1.0	536
17	ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients WithÂStable Ischemic HeartÂDisease. Journal of the American College of Cardiology, 2017, 69, 2212-2241.	1.2	513
18	Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. New England Journal of Medicine, 2017, 376, 32-40.	13.9	494

#	Article	IF	CITATIONS
19	Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR _{CT} : outcome and resource impacts study. European Heart Journal, 2015, 36, 3359-3367.	1.0	467
20	Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2013, 127, 224-232.	1.6	463
21	ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization. Journal of the American College of Cardiology, 2009, 53, 530-553.	1.2	462
22	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	1.0	458
23	ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update. Journal of the American College of Cardiology, 2012, 59, 857-881.	1.2	447
24	Relationship Between Infarct Size and Outcomes Following Primary PCI. Journal of the American College of Cardiology, 2016, 67, 1674-1683.	1.2	444
25	Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction. JAMA - Journal of the American Medical Association, 2014, 312, 1754.	3.8	430
26	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQqO 1444-1451.	0 0 rgBT / 6.3	Overlock 10 Tf 351
27	Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain. JAMA Cardiology, 2018, 3, 144.	3.0	349
28	Intra-aortic Balloon Counterpulsation and Infarct Size in Patients With Acute Anterior Myocardial Infarction Without Shock. JAMA - Journal of the American Medical Association, 2011, 306, 1329.	3.8	348
29	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation, 2014, 130, 138-146.	1.6	345
30	Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain. Circulation, 2017, 135, 2320-2332.	1.6	336
31	ACCF/ASNC Appropriateness Criteria for Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI). Journal of the American College of Cardiology, 2005, 46, 1587-1605.	1.2	332
32	ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 Appropriateness Criteria for Transthoracic and Transesophageal EchocardiographyâŽâŽDeveloped in accordance with the principles and methodology outlined by ACCF: Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson E, Wolk MJ, Allen JM, Raskin IE. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J	1.2	328
33	Am Coll Cardiol 2005;46:1606-13 (1) Journal of the American College of Cardiology, 2007, 50, 187-204. Appropriateness of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2011, 306, 53-61.	3.8	314
34	1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease. Journal of the American College of Cardiology, 2016, 68, 435-445.	1.2	313
35	Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurology, The, 2012, 11, 315-322.	4.9	310
36	ACCF Proposed Method for Evaluating the Appropriateness of Cardiovascular Imaging. Journal of the American College of Cardiology, 2005, 46, 1606-1613.	1.2	300

#	Article	IF	CITATIONS
37	Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Annals of Internal Medicine, 2008, 148, 16.	2.0	296
38	Detection of Left Ventricular Thrombus by Delayed-Enhancement Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2008, 52, 148-157.	1.2	271
39	ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization. Circulation, 2009, 119, 1330-1352.	1.6	271
40	Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. European Heart Journal, 2017, 38, 3502-3510.	1.0	271
41	Evaluation and Treatment of Patients With Lower Extremity Peripheral ArteryÂDisease. Journal of the American College of Cardiology, 2015, 65, 931-941.	1.2	269
42	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal, 2015, 36, 288-296.	1.0	266
43	Extent, Location, and Clinical Significance of Non–Infarct-Related Coronary Artery Disease Among Patients With ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2014, 312, 2019.	3.8	263
44	Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative. American Heart Journal, 2005, 149, 1043-1049.	1.2	256
45	Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry. Genetics in Medicine, 2009, 11, 790-796.	1.1	252
46	Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. Journal of the American College of Cardiology, 2013, 61, 1998-2006.	1.2	240
47	Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2014, 129, 1850-1859.	1.6	234
48	Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. American Heart Journal, 2014, 167, 846-852.e2.	1.2	218
49	Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link!. Journal of the American College of Cardiology, 2012, 60, 951-956.	1.2	216
50	Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry. European Heart Journal, 2018, 39, 3701-3711.	1.0	214
51	Factors Associated With Major Bleeding Events. Journal of the American College of Cardiology, 2014, 63, 891-900.	1.2	212
52	Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2015, 314, 2045.	3.8	212
53	1-Year Impact on Medical Practice and Clinical Outcomes of FFRCT. JACC: Cardiovascular Imaging, 2020, 13, 97-105.	2.3	204
54	SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes. Circulation, 2021, 144, 256-266.	1.6	204

#	Article	IF	CITATIONS
55	Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2011, 305, 1863.	3.8	203
56	ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 Appropriate Use Criteria for Diagnostic Catheterization. Journal of the American College of Cardiology, 2012, 59, 1995-2027.	1.2	188
57	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. Stroke, 2014, 45, 1304-1312.	1.0	187
58	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 651-658.	1.2	181
59	Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. Journal of the American Heart Association, 2013, 2, e000067.	1.6	179
60	Prevalence, predictors, and outcomes of patients with non–ST-segment elevation myocardial infarction and insignificant coronary artery disease: Results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. American Heart Journal, 2006, 152, 641-647.	1.2	171
61	Nonvitamin K Anticoagulant Agents inÂPatients With Advanced Chronic KidneyÂDisease or on Dialysis With AF. Journal of the American College of Cardiology, 2016, 67, 2888-2899.	1.2	171
62	High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. American Heart Journal, 2013, 165, 809-815.e1.	1.2	166
63	Quality-of-Life and Economic Outcomes ofÂAssessing Fractional Flow Reserve With Computed Tomography Angiography. Journal of the American College of Cardiology, 2015, 66, 2315-2323.	1.2	164
64	Gastrointestinal Bleeding in Patients WithÂAtrial Fibrillation Treated With Rivaroxaban or Warfarin. Journal of the American College of Cardiology, 2015, 66, 2271-2281.	1.2	159
65	Temporal Trends and Geographic Variation of Lower-Extremity Amputation in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2012, 60, 2230-2236.	1.2	158
66	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European Heart Journal, 2014, 35, 3377-3385.	1.0	154
67	Missed Opportunities. Circulation, 2012, 126, 1345-1354.	1.6	147
68	Blinded Physiological Assessment of Residual Ischemia After Successful Angiographic Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1991-2001.	1.1	147
69	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European Heart Journal, 2014, 35, 1873-1880.	1.0	145
70	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. Stroke, 2014, 45, 1739-1747.	1.0	142
71	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2016, 133, 352-360.	1.6	141
72	Trends in Settings for Peripheral Vascular Intervention and the Effect of Changes inÂthe Outpatient Prospective PaymentÂSystem. Journal of the American College of Cardiology, 2015, 65, 920-927.	1.2	138

#	Article	IF	CITATIONS
73	Arteriotomy Closure Devices for Cardiovascular Procedures. Circulation, 2010, 122, 1882-1893.	1.6	136
74	Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban. Clinical Cardiology, 2015, 38, 63-68.	0.7	135
75	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. Circulation, 2016, 134, 37-47.	1.6	134
76	Cardiovascular Events in Patients With Fabry Disease. Journal of the American College of Cardiology, 2011, 57, 1093-1099.	1.2	132
77	Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet, The, 2022, 399, 1383-1390.	6.3	131
78	Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1280-1289.	1.2	129
79	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart lournal, 2015, 170, 675-682,e8.	1.2	128
80	Cause of Death and Predictors of All ause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 2016, 5, e002197.	1.6	127
81	Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet, The, 2014, 384, 1187-1195.	6.3	123
82	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet, The, 2015, 385, 2363-2370.	6.3	123
83	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
84	CMR Imaging With Rapid Visual T1 Assessment Predicts Mortality in Patients Suspected of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 143-156.	2.3	116
85	Appropriate Use of Cardiovascular Technology. Journal of the American College of Cardiology, 2013, 61, 1305-1317.	1.2	114
86	ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 Appropriateness Criteria for Stress Echocardiography. Circulation, 2008, 117, 1478-1497.	1.6	112
87	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. Circulation, 2017, 135, 241-250.	1.6	111
88	PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal, 2014, 167, 796-803.e1.	1.2	104
89	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). American Heart Journal, 2018, 199, 83-91.	1.2	104
90	Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation: Heart Failure, 2013, 6, 740-747.	1.6	102

#	Article	IF	CITATIONS
91	Stroke in Young Black Patients. Stroke, 1995, 26, 1995-1998.	1.0	102
92	Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. Journal of Medical Genetics, 2016, 53, 495-502.	1.5	101
93	Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia. American Heart Journal, 2014, 167, 489-498.e7.	1.2	96
94	Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial. Journal of the American Heart Association, 2014, 3, e000521.	1.6	94
95	Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. European Journal of Preventive Cardiology, 2015, 22, 317-325.	0.8	94
96	Hospital Variability in the Rate of Finding Obstructive Coronary Artery Disease at Elective, Diagnostic Coronary Angiography. Journal of the American College of Cardiology, 2011, 58, 801-809.	1.2	88
97	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	6.1	87
98	Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. American Journal of Cardiology, 2005, 95, 976-978.	0.7	85
99	Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. European Heart Journal, 2014, 35, 242-249.	1.0	82
100	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology, 2015, 22, 734-742.	0.8	82
101	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European Heart Journal, 2014, 35, 233-241.	1.0	81
102	ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease. Journal of Nuclear Cardiology, 2017, 24, 1759-1792.	1.4	81
103	Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing. JAMA Cardiology, 2017, 2, 400.	3.0	80
104	Acute Limb Ischemia in Peripheral Artery Disease. Circulation, 2019, 140, 556-565.	1.6	80
105	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 145-152.	1.8	75
106	Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry. Genetics in Medicine, 2013, 15, 958-965.	1.1	74
107	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq1 1 0.78	84314 rgBT 0.7	Överlock 1.0 74
108	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. European Heart Journal, 2019, 40, 743-751.	1.0	70

#	Article	IF	CITATIONS
109	Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease. JAMA Network Open, 2018, 1, e185239.	2.8	68
110	A teamâ€based approach to patients in cardiogenic shock. Catheterization and Cardiovascular Interventions, 2016, 88, 424-433.	0.7	67
111	Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 541-549.	0.9	65
112	Cardiovascular and Limb Outcomes in Patients With Diabetes and PeripheralÂArtery Disease. Journal of the American College of Cardiology, 2018, 72, 3274-3284.	1.2	64
113	Splanchnic Nerve Block for Acute Heart Failure. Circulation, 2018, 138, 951-953.	1.6	62
114	Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19. Journal of Cardiovascular Translational Research, 2020, 13, 894-899.	1.1	62
115	Patient Selection for Diagnostic Coronary Angiography and Hospital-Level Percutaneous Coronary Intervention Appropriateness. JAMA Internal Medicine, 2014, 174, 1630.	2.6	61
116	The Impact of Coronary Physiology on Contemporary Clinical Decision Making. JACC: Cardiovascular Interventions, 2020, 13, 1617-1638.	1.1	60
117	A Comparison of Acute Coronary Syndrome Care at Academic and Nonacademic Hospitals. American Journal of Medicine, 2007, 120, 40-46.	0.6	59
118	Lower extremity amputation in peripheral artery disease: improving patient outcomes. Vascular Health and Risk Management, 2014, 10, 417.	1.0	59
119	Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis. American Heart Journal, 2015, 169, 924-937.e3.	1.2	59
120	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation, 2020, 142, 2219-2230.	1.6	58
121	Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials. European Heart Journal, 2017, 38, 1656-1663.	1.0	56
122	Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. European Heart Journal, 2018, 39, 4255-4256.	1.0	54
123	Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA). British Journal of Sports Medicine, 2022, 56, 913-918.	3.1	53
124	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm, 2014, 11, 925-932.	0.3	52
125	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. American Heart Journal, 2016, 179, 77-86.	1.2	51
126	Polyvascular Disease. Circulation: Cardiovascular Interventions, 2019, 12, e007385.	1.4	51

#	Article	IF	CITATIONS
127	The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease. Circulation, 2015, 132, 1999-2011.	1.6	50
128	Randomized Trials Versus CommonÂSense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
129	Central Core Laboratory versus Site Interpretation of Coronary CT Angiography: Agreement and Association with Cardiovascular Events in the PROMISE Trial. Radiology, 2018, 287, 87-95.	3.6	49
130	Effects of a 12-Week mHealth Program on FunctionalCapacity and Physical Activity in Patients With PeripheralArtery Disease. American Journal of Cardiology, 2018, 122, 879-884.	0.7	49
131	Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. American Heart Journal, 2016, 178, 74-84.	1.2	48
132	Usefulness of Intra-aortic Balloon Pump Counterpulsation. American Journal of Cardiology, 2016, 117, 469-476.	0.7	47
133	Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy. Annals of Internal Medicine, 2013, 158, 861.	2.0	46
134	High-Sensitivity Troponin I and CoronaryÂComputed Tomography inÂSymptomatic Outpatients WithÂSuspected CAD. JACC: Cardiovascular Imaging, 2019, 12, 1047-1055.	2.3	46
135	Co-existence of vascular disease in different arterial beds: Peripheral artery disease and carotid artery stenosis – Data from Life Line Screening®. Atherosclerosis, 2015, 241, 687-691.	0.4	45
136	Rationale, design and goals of the HeartFlow assessing diagnostic value of non-invasive FFR CT in Coronary Care (ADVANCE) registry. Journal of Cardiovascular Computed Tomography, 2017, 11, 62-67.	0.7	45
137	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. European Heart Journal, 2019, 40, 1492-1500.	1.0	45
138	Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis. Heart, 2022, 108, 194-202.	1.2	45
139	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). American Heart Journal, 2014, 168, 588-596.	1.2	44
140	The External Validity of Prediction Models for the Diagnosis of Obstructive CoronaryÂArtery Disease in Patients WithÂStable Chest Pain. JACC: Cardiovascular Imaging, 2018, 11, 437-446.	2.3	44
141	Splanchnic Nerve Block for ChronicÂHeartÂFailure. JACC: Heart Failure, 2020, 8, 742-752.	1.9	44
142	Sex Differences in Coronary Computed Tomography Angiography–Derived Fractional Flow Reserve. JACC: Cardiovascular Imaging, 2020, 13, 2576-2587.	2.3	42
143	ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization. Catheterization and Cardiovascular Interventions, 2009, 73, E1-24.	0.7	41
144	Comparative Effectiveness of Drug-Eluting Versus Bare-Metal Stents in Elderly Patients Undergoing Revascularization of Chronic Total Coronary Occlusions. JACC: Cardiovascular Interventions, 2012, 5, 1054-1061.	1.1	41

#	Article	IF	CITATIONS
145	Peripheral Arterial Testing Before Lower Extremity Amputation Among Medicare Beneficiaries, 2000 to 2010. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 142-150.	0.9	41
146	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003070.	1.4	41
147	Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. American Heart Journal, 2016, 175, 86-93.	1.2	41
148	Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI. Journal of the American College of Cardiology, 2020, 75, 1743-1754.	1.2	41
149	Clinical Trials in Peripheral Vascular Disease. Circulation, 2014, 130, 1812-1819.	1.6	40
150	Adherence to Guidelineâ€Recommended Therapy—Including Supervised Exercise Therapy Referral—Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. Journal of the American Heart Association, 2020, 9, e012541.	1.6	40
151	End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 470-478.	0.9	39
152	Cardiovascular Outcomes After LowerÂExtremity Endovascular or SurgicalÂRevascularization. Journal of the American College of Cardiology, 2018, 72, 1563-1572.	1.2	39
153	PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease:) Tj ETQq1	1 0.78431	4 rggT /Overle
154	Lymphatic Dysregulation in Patients WithÂHeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 66-76.	1.2	38
155	Acute Myocardial Infarction: Safety of Cardiac MR Imaging after Percutaneous Revascularization with Stents. Radiology, 2006, 240, 674-680.	3.6	37
156	Pexelizumab and Infarct Size in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Imaging, 2010, 3, 52-60.	2.3	37
157	Hospital Percutaneous Coronary Intervention Appropriateness and In-Hospital Procedural Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 290-297.	0.9	37
158	Determinants of Rejection Rate for Coronary CT Angiography Fractional Flow Reserve Analysis. Radiology, 2019, 292, 597-605.	3.6	37
159	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. European Journal of Heart Failure, 2021, 23, 1076-1084.	2.9	37
160	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart, 2016, 102, 1036-1043.	1.2	36
161	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). American Journal of Cardiology, 2017, 120, 588-594.	0.7	36
162	Twenty-Four–Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. Circulation, 2018, 138, 1602-1604.	1.6	36

#	Article	IF	CITATIONS
163	Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain. Journal of the American College of Cardiology, 2019, 73, 251-260.	1.2	36
164	Impact of calcification on percutaneous coronary intervention: MACEâ€Trial 1â€year results. Catheterization and Cardiovascular Interventions, 2019, 94, 187-194.	0.7	36
165	Quality-of-Life Outcomes With Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients With Suspected Coronary Artery Disease. Circulation, 2016, 133, 1995-2007.	1.6	35
166	Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Molecular Genetics and Metabolism, 2016, 119, 151-159.	0.5	35
167	1-Year Outcomes of Blinded Physiological Assessment of ResidualÂIschemia After Successful PCI. JACC: Cardiovascular Interventions, 2022, 15, 52-61.	1.1	35
168	Downstream procedures and outcomes after stress testing for chest pain without known coronary artery disease in the United States. American Heart Journal, 2012, 163, 454-461.	1.2	33
169	Stroke in Patients With Peripheral Artery Disease. Stroke, 2019, 50, 1356-1363.	1.0	33
170	Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2021, 14, e009879.	1.4	33
171	Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). American Journal of Cardiology, 2005, 95, 614-618.	0.7	32
172	Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. New England Journal of Medicine, 2016, 374, 785-788.	13.9	32
173	Identifying the Infarct-Related Artery in Patients With Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2019, 12, e007305.	1.4	32
174	Comparative Effectiveness of Medical Therapy, Supervised Exercise, and Revascularization for Patients With Intermittent Claudication: A Network Metaâ€analysis. Clinical Cardiology, 2015, 38, 378-386.	0.7	31
175	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace, 2016, 18, 1135-1142.	0.7	31
176	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. Circulation, 2017, 135, 1001-1003.	1.6	30
177	Raising the pressure: Hemodynamic effects of splanchnic nerve stimulation. Journal of Applied Physiology, 2017, 123, 126-127.	1.2	30
178	Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. American Heart Journal, 2017, 184, 1-9.	1.2	30
179	Incidence and predictors of lesion-specific ischemia by FFRCT: Learnings from the international ADVANCE registry. Journal of Cardiovascular Computed Tomography, 2018, 12, 95-100.	0.7	30
180	Sex-Specific Risks of MajorÂCardiovascular and LimbÂEventsÂinÂPatients With Symptomatic Peripheral Artery Disease. Journal of the American College of Cardiology, 2020, 75, 608-617.	1.2	30

#	Article	IF	CITATIONS
181	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PADÂTrial. Journal of the American College of Cardiology, 2021, 78, 317-326.	1.2	30
182	Intra-aortic balloon counterpulsation reduces mortality in large anterior myocardial infarction complicated by persistent ischaemia: a CRISP-AMI substudy. EuroIntervention, 2015, 11, 286-292.	1.4	30
183	Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. American Heart Journal, 2010, 160, 272-278.	1.2	29
184	Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine, 2018, 23, 523-530.	0.8	29
185	PREPARED Study: A Study of Shared Decision-Making for Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005244.	0.9	29
186	Firstâ€inâ€human experience with Aortix intraaortic pump. Catheterization and Cardiovascular Interventions, 2019, 93, 428-433.	0.7	29
187	Comparative Effectiveness Review of Antiplatelet Agents in Peripheral Artery Disease. Journal of the American Heart Association, 2014, 3, e001330.	1.6	28
188	Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. European Journal of Vascular and Endovascular Surgery, 2018, 55, 109-117.	0.8	28
189	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in HeartÂFailure. JACC: Heart Failure, 2021, 9, 293-300.	1.9	28
190	Predictive Model for High-Risk Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2019, 12, e007940.	1.3	27
191	Endovascular treatment of femoroâ€popliteal lesions. Clinical Cardiology, 2019, 42, 175-183.	0.7	27
192	Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the <scp>REBALANCEâ€HF</scp> trial rollâ€in cohort. European Journal of Heart Failure, 2022, 24, 1410-1414.	2.9	27
193	Association of the ankle-brachial index with history of myocardial infarction and stroke. American Heart Journal, 2014, 167, 499-505.	1.2	26
194	Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Current Medical Research and Opinion, 2016, 32, 1277-1279.	0.9	26
195	The Effect of Clinical Care Location onÂClinical Outcomes After PeripheralÂVascular Intervention in Medicare Beneficiaries. JACC: Cardiovascular Interventions, 2017, 10, 1161-1171.	1.1	26
196	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. JAMA Cardiology, 2019, 4, 7.	3.0	26
197	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008018.	1.4	25
198	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. American Journal of Cardiology, 2020, 126, 94-102.	0.7	25

#	Article	IF	CITATIONS
199	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation, 2021, 144, 1104-1116.	1.6	25
200	The Study Of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale. American Heart Journal, 2012, 164, 646-653.e3.	1.2	24
201	Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. American Heart Journal, 2015, 170, 400-408.e1.	1.2	24
202	Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. American Heart Journal, 2010, 160, 795-803.e2.	1.2	23
203	Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes. American Heart Journal, 2016, 173, 57-66.	1.2	23
204	Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006399.	0.9	23
205	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 77, 3016-3027.	1.2	23
206	Intra-aortic Balloon Pump Trials. Circulation: Cardiovascular Interventions, 2013, 6, 317-321.	1.4	22
207	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1694-1702.	1.1	21
208	Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. Journal of the American Heart Association, 2018, 7, e008755.	1.6	21
209	Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial. American Heart Journal, 2019, 208, 28-36.	1.2	20
210	Trans-lesional fractional flow reserve gradient as derived from coronary CT improves patient management: ADVANCE registry. Journal of Cardiovascular Computed Tomography, 2022, 16, 19-26.	0.7	20
211	Limb Ischemia: Cardiovascular Diagnosis and Management from Head to Toe. Current Cardiology Reports, 2015, 17, 611.	1.3	19
212	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation, 2021, 144, 1831-1841.	1.6	19
213	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral ArteryÂRevascularization. Journal of the American College of Cardiology, 2021, 78, 1768-1778.	1.2	19
214	Clinical trial issues in weight-loss therapy. American Heart Journal, 2006, 151, 633-642.	1.2	18
215	A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: Rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial. American Heart Journal. 2011, 162, 47-55.e1.	1.2	18
216	Appropriate Use Criteria to Reduce Underuse and Overuse. Journal of the American College of Cardiology, 2012, 60, 1885-1887.	1.2	18

#	Article	IF	CITATIONS
217	Detecting Obstructive Coronary Disease With CT Angiography and Noninvasive Fractional Flow Reserve. JAMA - Journal of the American Medical Association, 2012, 308, 1269.	3.8	18
218	Antithrombotic Therapy in PeripheralÂArteryÂDisease. Journal of the American College of Cardiology, 2018, 71, 352-362.	1.2	18
219	Non-hyperaemic coronary pressure measurements to guide coronary interventions. Nature Reviews Cardiology, 2020, 17, 629-640.	6.1	18
220	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. European Journal of Preventive Cardiology, 2022, 29, e181-e189.	0.8	18
221	Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials. American Heart Journal, 2017, 188, 18-25.	1.2	17
222	Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis, 2020, 315, 10-17.	0.4	17
223	Cardiovascular Outcomes in Collegiate Athletes After SARS-CoV-2 Infection: 1-Year Follow-Up From the Outcomes Registry for Cardiac Conditions in Athletes. Circulation, 2022, 145, 1690-1692.	1.6	17
224	Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease. American Heart Journal, 2019, 217, 42-51.	1.2	16
225	Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006512.	0.9	16
226	The Privilege of Self-Regulation. Journal of the American College of Cardiology, 2011, 57, 1557-1559.	1.2	15
227	Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts study. American Heart Journal, 2015, 170, 438-446.e44.	1.2	15
228	Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2017, 119, 753-759.	0.7	15
229	Analysis of Geographic Variations in the Diagnosis and Treatment of Patients With Aortic Stenosis in North Carolina. American Journal of Cardiology, 2014, 113, 1874-1878.	0.7	14
230	Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. American Heart Journal, 2016, 179, 10-18.	1.2	14
231	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. American Journal of Medicine, 2016, 129, 1117-1123.e2.	0.6	14
232	Potential Association of the ISCHEMIA Trial With the Appropriate Use Criteria Ratings for Percutaneous Coronary Intervention in Stable Ischemic Heart Disease. JAMA Internal Medicine, 2020, 180, 1540.	2.6	14
233	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2020, 50, 20-29.	1.0	14
234	Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010304.	2.1	14

#	Article	IF	CITATIONS
235	Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors. JACC: Cardiovascular Interventions, 2022, 15, 1167-1175.	1.1	14
236	Morbidity and Mortality Conference for Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	13
237	Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry. ASAIO Journal, 2018, 64, 218-224.	0.9	13
238	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. European Heart Journal, 2021, 42, 4040-4048.	1.0	13
239	The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial. American Heart Journal, 2022, 245, 136-148.	1.2	13
240	Importance of Total Ischemic Time and Preprocedural Infarct-Related Artery Blood Flow in Predicting Infarct Size in Patients With Anterior Wall Myocardial Infarction (from the CRISP-AMI Trial). American Journal of Cardiology, 2013, 112, 911-917.	0.7	12
241	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. Journal of the American Heart Association, 2015, 4, e001349.	1.6	12
242	Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. JACC: Clinical Electrophysiology, 2019, 5, 1384-1392.	1.3	12
243	The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease. American Heart Journal, 2021, 239, 135-146.	1.2	12
244	A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. American Heart Journal, 2020, 225, 3-9.	1.2	12
245	Pharmacological Treatment of Elderly Patients with Acute Coronary Syndromes without Persistent ST Segment Elevation. Drugs and Aging, 2002, 19, 633-646.	1.3	11
246	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Thrombosis Research, 2017, 156, 184-190.	0.8	11
247	CHA 2 DS 2 -VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. Annals of Emergency Medicine, 2017, 69, 541-550.e1.	0.3	11
248	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. Clinical Cardiology, 2018, 41, 39-45.	0.7	11
249	Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. Progress in Cardiovascular Diseases, 2018, 60, 514-523.	1.6	11
250	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. American Heart Journal, 2021, 233, 48-58.	1.2	11
251	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Network Open, 2022, 5, e2215580.	2.8	11
252	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) Tj ETQqO	0 0 rgBT /0	verlock 10 Tf

Cardiology, 2017, 120, 1837-1840.

ARTICLE IF CITATIONS Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 105-120. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from 254 0.8 10 ROCKET AF. International Journal of Cardiology, 2018, 257, 78-83. Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the) Tj ETQq1 1 0.784314 rgBT Overld Ankle-brachial index in patients with intermittent claudication is a poor indicator of patient-centered 256 0.6 10 and clinician-based evaluations of functional status. Journal of Vascular Surgery, 2019, 69, 906-912. Cause of Death Among Patients With Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006550. 258 Renal Denervation for Patients With Heart Failure. Circulation: Heart Failure, 2021, 14, e008301. 10 1.6 Model-Based Algorithms for Detecting Peripheral Artery Disease Using Administrative Data From an Electronic Health Record Data System: Algorithm Development Study. JMIR Medical Informatics, 2020, 1.3 10 8, e18542. Phenomeâ€Wide Association Study of Severe COVIDâ€19 Genetic Risk Variants. Journal of the American 260 1.6 10 Heart Association, 2022, 11, e024004. Incidence, timing, and type of first and recurrent ischemic events in patients with and without 1.2 peripheral artery disease after an acute coronary syndrome. American Heart Journal, 2018, 201, 25-32. Clinical Impact of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve on 262 0.7 9 Japanese Population in the ADVANCE Registry. Circulation Journal, 2019, 83, 1293-1301. Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review. American Heart Journal, 2020, 229, 52-60. Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. European Heart 264 1.4 9 Journal - Cardiovascular Pharmacotherapy, 2022, 8, 825-836. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, . Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: 266 1.6 8 Observations From the ROCKET AF Trial. Journal of the American Heart Association, 2017, 6, . National patterns in intensity and frequency of outpatient care for apparent treatment-resistant 1.2 hypertension. American Heart Journal, 2017, 186, 29-39. Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. American Heart Journal, 2020, 220, 51-58. 268 1.2 8 Randomized trial for answers to clinical questions: evaluating a pre-appraised versus a MEDLINE 269 0.6 search protocol. Journal of the Medical Library Association: JMLA, 2006, 94, 382-7. Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation. Heart Rhythm, 2022, 19, 270 0.3 8 1237-1244.

#	Article	IF	CITATIONS
271	Sexâ€Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American Heart Association, 2022, 11, .	1.6	8
272	Noninvasive imaging for coronary artery disease: A technology assessment for the Medicare Coverage Advisory Commission. American Heart Journal, 2007, 153, 161-174.	1.2	7
273	Aborted myocardial infarction after primary percutaneous coronary intervention: Magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. American Heart Journal, 2013, 165, 226-233.	1.2	7
274	Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?. European Heart Journal, 2014, 35, 1834-1835.	1.0	7
275	Use of Appropriate Use Criteria Is Increasing, but What Are Their Effects on Medical Care?. Circulation, 2015, 132, 4-6.	1.6	7
276	Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e005628.	1.4	7
277	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal, 2019, 218, 110-122.	1.2	7
278	Sham trials: benefits and risks for cardiovascular research and patients. Lancet, The, 2019, 393, 2104-2106.	6.3	7
279	Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2020, 13, e009326.	1.4	7
280	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq0 0 0 e016573.	rgBT /Ove 1.6	rloçk 10 Tf 50
281	The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. JACC: Cardiovascular Interventions, 2021, 14, 796-802.	1.1	7
282	A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 75, 1762-1775.	0.6	7
283	Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. American Heart Journal, 2012, 163, 797-803.	1.2	6
284	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. American Heart Journal, 2018, 200, 102-109.	1.2	6
285	Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. Clinical Cardiology, 2018, 41, 137-143.	0.7	6
286	Identification, diagnosis, treatment, and in-hospital outcomes of acute pulmonary embolism: Results from a single integrated health system. American Heart Journal, 2019, 216, 136-142.	1.2	6
287	Impact of Procedural Bleeding in Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008069.	1.4	6
288	The clinical utility of FFRCT stratified by age. Journal of Cardiovascular Computed Tomography, 2021, 15, 121-128.	0.7	6

#	Article	IF	CITATIONS
289	Acute cardiovascular hospitalizations and illness severity before and during the <scp>COVID</scp> â€19 pandemic. Clinical Cardiology, 2021, 44, 656-664.	0.7	6
290	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. International Journal of COPD, 2021, Volume 16, 841-851.	0.9	6
291	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. Atherosclerosis, 2021, 338, 1-6.	0.4	6
292	One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011506.	1.4	6
293	Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R ₂ ´CHADS ₂ Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition) Tj ETQq1 1 0.7	784314 rgB ⁻ 1.6	T {Overlock
294	2013, 128, e172-3. Edoxaban and the need for outcomes-based NOAC dosing. Lancet, The, 2015, 385, 2232-2233.	6.3	5
295	Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). American Journal of Medicine, 2016, 129, 1307-1315.	0.6	5
296	Temporal changes in FFRCT-Guided Management of Coronary Artery Disease – Lessons from the ADVANCE Registry. Journal of Cardiovascular Computed Tomography, 2021, 15, 48-55.	0.7	5
297	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. Diabetic Medicine, 2021, 38, e14552.	1.2	5
298	Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease Questionnaire. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007232.	0.9	5
299	National trends in repair for type B aortic dissection. Clinical Cardiology, 2021, 44, 1058-1068.	0.7	5
300	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Network Open, 2021, 4, e2117963.	2.8	5
301	Pexelizumab: A novel therapy for mycardial ischemia-reperfusion. Drugs of Today, 2005, 41, 165.	2.4	5
302	Patient-Reported Outcome Measures in Symptomatic, Non–Limb-Threatening Peripheral Artery Disease: A State-of-the-Art Review. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011320.	1.4	5
303	Access site for cardiac catheterization. American Heart Journal, 2004, 147, 1-2.	1.2	4
304	Appropriateness of Percutaneous Coronary Intervention: A Review. Current Cardiology Reports, 2013, 15, 379.	1.3	4
305	Ischemia-Driven Revascularization. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 250-252.	0.9	4
306	Letter response. American Heart Journal, 2015, 170, e5-e6.	1.2	4

#	Article	IF	CITATIONS
307	The Early Invasive Strategy in AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2015, 66, 521-523.	1.2	4
308	Evaluation of Cardiac Magnetic Resonance as a Surrogate in ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 115, 1607-1614.	0.7	4
309	A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. Current Medical Research and Opinion, 2017, 33, 1717-1723.	0.9	4
310	The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. Cardiovascular Drugs and Therapy, 2017, 31, 433-444.	1.3	4
311	Percutaneous Support Devices for Percutaneous Coronary Intervention. Circulation, 2019, 139, 347-350.	1.6	4
312	Practice Pattern, Diagnostic Yield, and Longâ€īerm Prognostic Impact of Coronary Computed Tomographic Angiography. Journal of the American Heart Association, 2020, 9, e016620.	1.6	4
313	Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. American Heart Journal, 2021, 233, 59-67.	1.2	4
314	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Non–ST-Segment–Elevation Myocardial Infarction for Intensive Care Unit Admission. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007602.	0.9	4
315	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. American Heart Journal, 2021, 236, 4-12.	1.2	4
316	Ambient temperature and infarct size, microvascular obstruction, left ventricular function and clinical outcomes after ST-segment elevation myocardial infarction. Coronary Artery Disease, 2022, 33, 81-90.	0.3	4
317	A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study. American Heart Journal, 2021, 239, 19-26.	1.2	4
318	The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?. Current Cardiology Reports, 2021, 23, 13.	1.3	4
319	Electrocardiographic findings in young competitive athletes during acute SARS-CoV-2 infection. Journal of Electrocardiology, 2022, 72, 13-15.	0.4	4
320	Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure. Journal of Cardiac Failure, 2022, 28, 1469-1474.	0.7	4
321	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. Journal of the American Heart Association, 2022, 11, .	1.6	4
322	Promise of Factor Xa Inhibition in Atrial Fibrillation. Current Cardiology Reports, 2012, 14, 70-78.	1.3	3
323	Combined Use of Warfarin and Oral <scp>P2Y12</scp> Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome. Clinical Cardiology, 2014, 37, 152-159.	0.7	3
324	Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF― Circulation, 2016, 134, e532-e533.	1.6	3

#	Article	IF	CITATIONS
325	Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial. American Heart Journal, 2016, 174, 7-13.	1.2	3
326	Oral Anticoagulation in Patients with End Stage Renal Disease and Atrial Fibrillation. Circulation, 2016, 133, 242-244.	1.6	3
327	Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European Heart Journal, 2019, 40, 1568-1568.	1.0	3
328	The impact of chronic kidney disease on outcomes following peripheral vascular intervention. Clinical Cardiology, 2020, 43, 1308-1316.	0.7	3
329	Use of hospital resources in the care of patients with intermediate risk pulmonary embolism. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 273-278.	0.4	3
330	Younger patients with chronic limb threatening ischemia face more frequent amputations. American Heart Journal, 2021, 242, 6-14.	1.2	3
331	Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices. American Heart Journal, 2022, 244, 116-124.	1.2	3
332	Coronary volume to left ventricular mass ratio in patients with diabetes mellitus. Journal of Cardiovascular Computed Tomography, 2022, 16, 319-326.	0.7	3
333	Physician judgement in predicting obstructive coronary artery disease and adverse events in chest pain patients. Heart, 2022, , heartjnl-2021-320275.	1.2	3
334	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	1.9	3
335	To transfer or not to transfer: acute myocardial infarction reperfusion. American Heart Journal, 2004, 147, 573-574.	1.2	2
336	An Intracardiac Mass in a Young Man With Congenitally Acquired HIV. Cardiology in Review, 2004, 12, 126-130.	0.6	2
337	The Impact of Processes of Care on Myocardial Infarct Size in Patients With <scp>ST</scp> ‣egment Elevation Myocardial Infarction: Observations From the <scp>CRISPâ€AMI</scp> Trial. Clinical Cardiology, 2015, 38, 25-31.	0.7	2
338	Chronic Total Occlusion Trials. JACC: Cardiovascular Interventions, 2017, 10, 2171-2173.	1.1	2
339	Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?. Current Cardiology Reports, 2018, 20, 105.	1.3	2
340	Should a Meta-Analysis Guide OurÂPractice?. JACC: Cardiovascular Interventions, 2018, 11, 844-846.	1.1	2
341	Odyssey of Patent Foramen Ovale: Closure in Cryptogenic Stroke: The Canary in the Coal Mine of Clinical Trials?. Journal of the American Heart Association, 2018, 7, .	1.6	2
342	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. Cardiology and Therapy, 2019, 8, 283-295.	1.1	2

#	Article	IF	CITATIONS
343	Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized) Tj ETQq1	1 0.084314	⊧rg⁄BT /Overlo
344	CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. American Heart Journal, 2020, 229, 118-120.	1.2	2
345	SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention. Journal of Cardiovascular Pharmacology, 2020, 76, 189-196.	0.8	2
346	Intensive Training and Real-Time Quality Control by a Physiology Core Laboratory. Circulation: Cardiovascular Interventions, 2020, 13, e009077.	1.4	2
347	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circulation: Cardiovascular Interventions, 2021, 14, e009871.	1.4	2
348	Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. Journal of Vascular Surgery, 2022, 75, 660-670.e3.	0.6	2
349	Clinician specialty, access to care, and outcomes among patients with peripheral artery disease. American Journal of Medicine, 2021, , .	0.6	2
350	Abstract 18053: Prognostic Value of Anatomic versus Functional Diagnostic Testing in Symptomatic Patients With Suspected CAD: The PROMISE Trial (PROspective Multicenter Imaging Study for) Tj ETQq0 0 0 rg	BT / Dø erloo	k 120 Tf 50 45
351	Impact of risk factor control on peripheral artery disease outcomes and health disparities. Vascular Medicine, 2022, 27, 323-332.	0.8	2
352	Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation― Circulation, 2016, 134, e7-8.	1.6	1
353	Peripheral Artery Disease Therapies May Perform Differently inÂPractice Than in Randomized Trials. JACC: Cardiovascular Interventions, 2016, 9, 725-727.	1.1	1
354	Location, Location, Location. JACC: Cardiovascular Interventions, 2016, 9, 2400-2402.	1.1	1
355	Mature Technology for Mature Patients. JACC: Cardiovascular Interventions, 2018, 11, 889-891.	1.1	1
356	Ischaemic stroke in heart failure: back to basics?. Heart, 2020, 106, 555-556.	1.2	1
357	Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. Heart Rhythm O2, 2021, 2, 215-222.	0.6	1
358	Utility of High-Sensitivity Troponin Among Stable Patients With Chest Pain Undergoing Stress Imaging (from PROMISE). American Journal of Cardiology, 2021, 158, 148-149.	0.7	1
359	Crossing Peripheral Chronic Total Occlusions: More Tolls and More Questions. Journal of the American Heart Association, 2021, 10, e023423.	1.6	1
360	Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation. Clinical and Experimental Emergency Medicine, 2018, 5, 43-50.	0.5	1

#	Article	IF	CITATIONS
361	Effect of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve on Physicians' Clinical Behavior 〕 Differences Between Sites With and Without Appropriate Use Criteria as Designated by the Japanese Reimbursement System ―. Circulation Reports, 2020, 2, 364-371.	0.4	1
362	Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery. New England Journal of Medicine, 2022, 386, 1863-1866.	13.9	1
363	Which Î ² -blocker for heart failure?. American Heart Journal, 2004, 147, 238.	1.2	0
364	High Risk Percutaneous Coronary Intervention and Intra-Aortic Balloon Pumps. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 12-13.	0.9	0
365	Reply. Journal of the American College of Cardiology, 2013, 61, 2025-2026.	1.2	0
366	Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization― American Heart Journal, 2016, 171, e7.	1.2	0
367	Practice Variation in Patients Eligible forÂTriple Therapy. JACC: Clinical Electrophysiology, 2016, 2, 44-46.	1.3	0
368	Response by Jones et al to Letter Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease― Circulation, 2017, 135, e1109-e1110.	1.6	0
369	Patient-Reported Outcomes in Revascularization Decisions for Left-MainÂDisease. Journal of the American College of Cardiology, 2017, 70, 3123-3126.	1.2	0
370	Renal Dysfunction. Journal of the American College of Cardiology, 2019, 73, 2251-2252.	1.2	0
371	Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement. American Heart Journal, 2021, 233, 151-152.	1.2	0
372	Successful Peripheral Vascular Intervention in Patients with High-risk Comorbidities or Lesion Characteristics. Current Cardiology Reports, 2021, 23, 32.	1.3	0
373	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. Journal of the American Heart Association, 2021, 10, e022485.	1.6	0
374	Cardiovascular risk and outcomes in symptomatic patients with suspected coronary artery disease and non coronary vascular disease: A report from the PROMISE trial. American Heart Journal, 2021, 242, 82-91.	1.2	0
375	Abstract 16866: Blood Pressure Control and Stroke or Bleeding Risk in Patients with Atrial Fibrillation: Results from the ROCKET AF Trial. Circulation, 2014, 130, .	1.6	0
376	Abstract 17036: Uncontrolled Apparent Treatment Resistant Hypertension is Associated With Increased Hospitalization and Increased Total Hospital Reimbursements. Circulation, 2015, 132, .	1.6	0
377	Abstract 17083: SARS-CoV-2 Dramatically Decreases Healthcare Access for Patients With Cardiovascular Disease. Circulation, 2020, 142, .	1.6	0
378	The value of looking. Multiple myeloma discovered by an unusual finding in Gram-stained spinal fluid. North Carolina Medical Journal, 2002, 63, 129-30.	0.1	0

#	Article	IF	CITATIONS
379	Reply. JACC: Cardiovascular Interventions, 2022, 15, 793-794.	1.1	о
380	Abstract 16902: Efficacy and Safety of Rivaroxaban versus Warfarin in Patients Taking Non-dihydropyridine Calcium Channel Blockers: Results From the ROCKET AF Trial. Circulation, 2015, 132, .	1.6	0
381	Abstract 16914: On-treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation, 2015, 132, .	1.6	Ο